PR in the Philippines

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Artificial intelligence has many uses in daily life. From personalized shopping suggestions to voice assistants and real-time fraud detection, AI is working behind the scenes to make experiences smoother and more seamless. Behind every smart AI feature is a process that involves two distinct stages: AI training and AI inference. While they're both essential to building intelligent systems, they serve very different purposes and have unique requirements. Let's break down the differences between training and inference.What is AI training?AI training is the process of feeding an AI model large volumes of data, so it learns to recognize patterns and generate the required output.Training generally requires large volumes of labeled or unlabeled data, each of which may facilitate different forms of training.Labeled data: Some projects require a model to make decisions or generate output based on established patterns or correlations. Here, it makes sense to train the model on labeled data using supervised learning techniques.Unlabeled data: Training models on unlabeled data lets them detect new patterns and build an understanding of the relationships between inputs and outputs. This is called unsupervised learning.Think of AI training like teaching a student using flashcards, quizzes, and feedback. During training, the model constantly adjusts internal parameters (often millions or billions of them) to minimize errors and improve accuracy. This phase is computationally intensive and requires specialized hardware like GPUs or TPUs to process large datasets efficiently.For example, training an AI model to recognize objects in images might involve showing it millions of labeled photos of cats, cars, and coffee mugs until it can correctly identify these objects on its own.What is AI inference?Once a model has been trained, it's ready to perform tasks. AI inference is the process of using a trained model to make predictions or decisions on new, unseen data.Inference is typically faster and more lightweight than training. It's used in real-time applications like chatbots, recommendation engines, voice recognition, and edge devices like smartphones or smart cameras. Inference is the test of training. If the output or predictions from your model are inaccurate, you may need to go back to testing.Going back to the earlier example, inference is what happens when you upload a photo to your phone and the AI instantly recognizes your pet as a "cat." The model has been trained to recognize cat images; it just applies what it already knows.Where AI training and inference differThough both stages are part of the same AI lifecycle, they differ significantly in purpose, speed, and system requirements. Here's a closer look at the key differences:ObjectiveTraining aims to teach the AI model by exposing it to data and helping it learn relationships, rules, and patterns.Inference uses the trained model to generate output (such as predictions, classifications, or decisions) based on new data.Time takenTraining can take hours, days, or even weeks, depending on the size of the model and the complexity of the data. It's a resource-heavy, iterative process.Inference happens much faster, often in real time or near real time.Infrastructure needsTraining requires high-performance computing resources such as powerful GPUs or TPUs, and large memory bandwidth. Most training happens in cloud environments or specialized data centers.Inference can often run on lower-powered devices, including edge hardware like mobile phones or IoT devices. Dedicated inference servers or GPU instances may still be needed in some cases.AI training and inference work hand in hand, but they have different goals, requirements, and challenges. Training is about teaching the model, and inference is about putting it to work. Organizations planning AI projects must consider both phases when budgeting, selecting hardware, and choosing infrastructure.CONTACT:Sonakshi MurzeManagersonakshi.murze@iquanti.comSOURCE: OneMain Financial Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that a Biologics License Application (“BLA”) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation (“CDE”) of the National Medical Products Administration (“NMPA”) in China. The product is jointly developed by the Group and Shanghai Henlius Biotech, Inc. (“Henlius”, Stock Code: 2696.HK) for the treatment of wet age-related macular degeneration (“wet-AMD”) in China.The phase 3 clinical trial of EB12-20145P (HLX04-O) among Chinese patients (“AURA-1”) has successfully reached the primary endpoint in April this year. AURA-1 is a multi-centre, randomised, double-blind, active-controlled, and non-inferiority phase 3 clinical trial which aimed to compare the efficacy and safety of EB12-20145P (HLX04-O) with that of ranibizumab administered by intravitreal injection (“IVT”) in newly diagnosed wet-AMD patients.In addition to AURA-1, the BLA of which has been validated by the NMPA, an international, multi-centre phase 3 clinical study of EB12-20145P (HLX04-O) in patients with wet-AMD is ongoing successively in several European countries, Australia, the United States, and China (“AURA-2”) with last patient last visit completed by January 2025. Moving forward, Essex will continue to strive for excellence by embracing innovation to develop first-in-class and best-in-class products, providing solutions for Tomorrow’s healthcare problems, Today.About wet-AMDAge-related macular degeneration (“AMD”) is one of the leading causes of visual impairment and blindness in the elderly worldwide [1]. According to the World Health Organization (WHO), about 30 million people have suffered from AMD globally, and about half a million people become blind due to AMD each year [2]. Wet age-related macular degeneration (“wet-AMD”) is characterised by the formation of subretinal choroidal neovascularization (CNV) and is responsible for approximately 90% of cases of AMD-related blindness. Due to an aging population, wet-AMD has become a serious social medical problem and indicated a huge burden of unmet need [3]. With the development of treatment for fundus diseases, anti-VEGF drugs are becoming the first-line therapy for the management of wet-AMD [4], and the efficacy and safety of vitreous injection of bevacizumab for wet-AMD have been verified in multiple clinical studies [5-11].About EssexEssex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,000 hospitals, supported by the Company’s 44 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.Reference[1] 2020(1).[2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51.[3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116.[4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292.[5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459.[6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908.[7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411.[8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9.[9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52.[11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - SGX Catalist-listed AsiaMedic Limited (the “Company” and, together with its subsidiaries, the “Group”) announced its unaudited financial results for the six months ended 30 June 2025 (“1H2025”), delivering 26% year-on-year revenue growth to S$16.6 million, up from S$13.2 million in 1H2024.This performance was led by the Group’s diagnostic imaging business, which contributed over 60% of total revenue, supported by strong demand at its flagship Shaw Centre clinic and contributions from the newly opened Novena imaging centre.Financial Highlights:Revenue up 26% to S$16.6 million, from S$13.2m in 1H2024, driven by strong growth in diagnostic imaging and steady performance in medical wellness.EBITDA attributable to owners of the Company was maintained at S$1.3 million, reflecting consistent contributions from core businesses, even as the new Novena centre incurred ramp-up losses.Net loss attributable to owners of the Company narrows significantly to S$38,603 from S$104,431 in 1H2024.Cash and cash equivalents stood at S$4.9 million, with an additional S$3.6 million in financial assets, reflecting strong underlying liquidity despite investments into Novena centre.Profitability was significantly affected by the new Novena imaging centre as it remains in its ramp-up phase. However, the Group’s financial performance reflects solid execution of its core business strategy amidst expansion.Mr Arifin Kwek (郭致宾), Chief Executive Officer of AsiaMedic Limited, said, “Our performance in the first half of 2025 reflects the continued strength of our diagnostic imaging business. Shaw Centre remained our primary growth engine with sustained patient volumes, while the newly opened Novena Centre, though still ramping up, has already begun contributing. These investments will further position us as a trusted provider of early detection and preventive care in Singapore.Our health screening and medical wellness segment remained stable, underpinned by the government awarded Grow Well SG programme and steady corporate wellness demand. While the opening of Novena has added to our cost, these are deliberate investments in capacity, technology, and skilled professionals in a key medical geographical location in Singapore, that position us for long term growth.We will continue to build on this foundation, focusing on scaling our imaging and health screening businesses while ensuring we deliver high quality, patient-centred care. With expanded capacity and prudent cost management, AsiaMedic is well placed to capture growth opportunities in Singapore’s healthcare sector.”As Singapore continues to position itself as a regional healthcare hub, AsiaMedic is well-placed to meet growing demand for accessible, high-quality diagnostic and preventive healthcare services. With established centres in Orchard and Novena — two of the country’s key medical precincts — the Group is strategically expanding its reach to serve a broader patient base. This geographic presence, supported by ongoing investments in technology, infrastructure, and clinical talent, positions AsiaMedic to play a meaningful role in advancing Singapore’s preventive care and early detection agenda.This media release should be read in conjunction with the financial statements announced on SGXNet.About AsiaMedic LimitedAsiaMedic Limited together with its subsidiaries (“AsiaMedic” or the “Group”) is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to preventand detect early illnesses to achieve positive experiences and clinical outcomes for patients. AsiaMedic is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (SGX-ST).The Group is committed to helping clients through practical and personalised solutions delivered with the highestprofessional standards of service and expertise in a timely, safe and consistent manner.With convenient locations at Orchard and Novena, AsiaMedic is a preferred one-stop centre for:Diagnostic imaging and radiology servicesMedical wellness and health screening servicesPrimary healthcare servicesMedical aesthetic services and productsFor more information, please visit www.asiamedic.com.sgFor media and analysts’ queries, please contact:Waterbrooks ConsultantsWayne KooT: (65) 9338 8166 / (65) 8901 9780E: wayne.koo@waterbrooks.com.sg / query@waterbrooks.com.sgThis announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examinedor approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Following the lifting of the Black Rainstorm Warning Signal at 11:10am, the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO and Hong Kong International Tea Fair will reopen at 1:10pm.The Food Expo, Beauty & Wellness Expo, Home Delights Expo will be extended and close at 11pm from 15 August to 17 August, allowing public visitors to enjoy shopping in these fairs—with a single ticket. The Food Expo PRO and Hong Kong International Tea Fair will remain open until 6pm today and tomorrow (14 to 15 August) and until 5pm on Saturday (16 August), enabling trade buyers and exhibitors to continue their business discussions.Admission tickets valid for today may be used for entry on any of the remaining fair days.Sessions 2 and 3 of the International Conference of the Modernization of Chinese Medicine afternoon programme will be resumed in a hybrid format.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - As the Black Rainstorm Warning Signal was issued at 7:50am, the opening of Food Expo, and the concurrent Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo, will be postponed. The opening ceremony originally scheduled for 10:30am, is cancelled. The International Conference of the Modernization of Chinese Medicine will be accessible via livestream.The organiser will make appropriate arrangements to ensure the safety of those already at the venue and will closely monitor the weather conditions. The organiser will open the Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo two hours after the Black Rainstorm Warning Signal is cancelled.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn Copyright 2025 ACN Newswire via SeaPRwire.com.

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding.  Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on  HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 13, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the resumption of work on the Environmental and Social Impact Assessment ("ESIA") for its 100%-owned Lac Knife flake graphite project located near Fermont, in the province's prolific iron ore mining district.The Company has formally re-engaged IOS Geosciences Inc. ("IOS"), a leading Québec-based geological consulting firm and former general contractor on the ESIA, to complete a total of sixteen (16) technical reports required for submission to Québec's environmental and natural resource authorities. These reports represent a major step in advancing the Lac Knife project toward permitting and the goal of mine construction.The ESIA program, initially launched in 2020, involves multidisciplinary technical evaluations and environmental baseline work conducted across 2020 and 2021. Finalization was delayed due to funding constraints but is now back on track. Report completion is estimated by early 2026, with submissions planned shortly thereafter to the Québec Ministry of Sustainable Development, Environment, and the Fight Against Climate Change ("MDDELCC"), as well as the Ministry of Natural Resources and Forests ("MRNF").The sixteen (16) technical reports in progress cover critical permitting areas, including:Condemnation and pit wall drillingAcid-generating potential analysisGeotechnical drilling and soil mechanicsSoil geochemistry and chemistry baselineLake-bottom geochemical and surface water quality surveysGroundwater habitat assessment and follow-upCaribou habitat assessment and follow-upGeometallurgical and graphite flake characterizationThese comprehensive studies are essential for satisfying Québec's rigorous environmental and social licensing requirements and underscore Focus Graphite's commitment to environmental stewardship and Indigenous engagement through project development.In parallel, Focus has also authorized IOS proceed with geochemical analysis of over 1,000 split and pulverized drill core samples collected from its 2022 exploration drilling program at the Lac Tétépisca ("Tétépisca") graphite project. The samples, targeting the Southwest MOGC and West Limb geophysical (MAG-EM) conductors, will undergo carbon and sulfur determinations at certified laboratories.Upon receipt of assays, IOS will finalize and submit the corresponding technical reports covering 14,900.5 metres of core drilling from 74 holes to the MRNF. An updated Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") and National Instrument ("NI") 43-101 compliant Mineral Resource Estimate ("MRE") for the Manicouagan-Ouest Graphitic Corridor ("MOGC") graphite deposit is anticipated in Fall 2025, which will further define Tétépisca's development potential alongside Lac Knife."Resuming the ESIA is a pivotal milestone that moves us closer to full permitting and our goal of mine development at Lac Knife," said Dean Hanisch, CEO of Focus Graphite. "With most fieldwork and laboratory studies already complete, we're in a strong position to finalize this critical stage efficiently. At the same time, initiating assay work at Tétépisca to support an upgraded mineral resource estimate reflects our commitment to building value across our entire Québec asset base."The Company also announced the grant of incentive stock options as compensation to its directors, officers, employees, and consultants. Options to purchase up to 4,215,000 Common Shares of the Company have been granted at an exercise price of $0.14 per share. The options expire on 13 August, 2030. Additionally, the Company has granted 1,350,000 restricted stock units ("RSUs") to officers, directors, and consultants of the Company under the terms of the Company's restricted share unit and equity incentive plan (the "RSU and EIP Plan"). Each RSU entitles the holder to acquire one common share of the Company after the vesting period in accordance with the Plan.Qualified PersonsThe technical content disclosed in this news release was reviewed and approved by Réjean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the completion and submission of the sixteen technical reports required for the Lac Knife Environmental and Social Impact Assessment, the anticipated timeline for ESIA report submission and permitting, the initiation and results of geochemical analyses at the Lac Tétépisca project, the anticipated updated NI 43-101 Mineral Resource Estimate for the Tétépisca deposit, the Company's positioning as a near- and long-term secure supplier of specialty graphite materials, and the potential geopolitical significance of Canadian graphite supply.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262450 Copyright 2025 ACN Newswire via SeaPRwire.com.